dc.contributor.author | Abinya, Nicholas O | |
dc.date.accessioned | 2013-07-26T08:29:12Z | |
dc.date.available | 2013-07-26T08:29:12Z | |
dc.date.issued | 2001 | |
dc.identifier.citation | Abinya, NAO, Nyabola IO. 2001. Experience with vincristine - associated neurotoxicity. | en |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/51525 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/pubmed/11957264 | |
dc.description.abstract | OBJECTIVES:
To evaluate the frequency and severity of occurrence of vincristine-associated neurotoxicity.
DESIGN:
A retrospective case series study.
SETTING:
Hurlingham Oncology Clinic, Nairobi.
SUBJECTS:
Thirty-eight patients treated for various neoplasms with vincristine containing chemotherapeutic regimens.
MAIN OUTCOME MEASURES:
The frequency and degree of neurotoxicity when vincristine was given at the standard dose of 1.4 mg/m2.
RESULTS:
Five patients (13.2%) developed peripheral neuropathy, one having had it even before vincristine was started. Therefore only four (10.5%) had it attributed to vincristine. Four of the patients who developed neuropathy (80%) were HIV-positive. Neuropathy grade 2 (severe) occurred in only two patients leading to discontinuation of the drug. All the neurotoxicity resolved after discontinuation of vincristine.
CONCLUSION:
Vincristine induced neuropathy occurred but was rarely severe at a dose of 1.4 mg/m2. It appeared to be more frequent in HIV infected individuals, but controlled studies with bigger sample sizes are required to determine whether this may warrant routine capping of the dose at a maximum of 2 mg. | |
dc.language.iso | en | en |
dc.publisher | University of Nairobi | en |
dc.title | Experience with vincristine - associated neurotoxicity | en |
dc.type | Article | en |
local.publisher | College of Health science | en |